


## CLAIMS

1. A compound having the following structure:



(I)

or a pharmaceutically acceptable salt, ester, solvate, stereoisomer or prodrug thereof,

wherein:

$R_1$  and  $R_2$  are the same or different and independently are hydrogen, alkyl, or substituted alkyl;

Ar is phenyl, phenyl substituted by 1 or 2  $R_3$ , pyridyl or pyridyl substituted by 1 or 2  $R_3$ ;

$R_3$  at each occurrence is independently alkyl, substituted alkyl, alkoxy, substituted alkoxy, cyano, halogen, alkylsulfinyl, or alkylsulfonyl;

Het is heterocycle or heterocycle substituted with 1 or 2  $R_4$ ;

$R_4$  at each occurrence is independently alkyl, substituted alkyl, alkoxy, substituted alkoxy, halogen, cyano or oxo; and

$R_5$  and  $R_6$  are the same or different and independently are hydrogen, alkyl or substituted alkyl.

2. A compound according to claim 1, wherein  $R_1$  is alkyl.

3. A compound according to claim 1, wherein  $R_2$  is alkyl or substituted alkyl.

4. A compound according to claim 1, wherein Ar is phenyl substituted by 1

$R_3$ .

5. A compound according to claim 4, wherein  $R_3$  is alkyl, substituted alkyl, alkoxy, cyano or halogen.
6. A compound according to claim 4, wherein  $R_3$  is halogen.
7. A compound according to claim 1, wherein Het is heterocycle substituted with 1  $R_4$ .
8. A compound according to claim 7, wherein  $R_4$  is alkyl, substituted alkyl, or alkoxy.
9. A compound according to claim 7, wherein  $R_4$  is oxo.
10. A compound according to claim 3, wherein  $R_5$  at each occurrence is hydrogen.
11. A compound according to claim 10, wherein Ar is phenyl, pyridyl or phenyl substituted by one  $R_3$ , wherein  $R_3$  is halogen.
12. A compound according to claim 11, wherein Ar is phenyl substituted by one  $R_3$ , and wherein  $R_3$  is chloro.
13. A compound according to claim 12, wherein Het is heterocycle.
14. A compound according to claim 13, wherein Het is pyrazole.
15. A compound according to claim 12, wherein Het is heterocycle substituted by one or two  $R_4$ .
16. A compound according to claim 15, wherein Het is dimethylisoxazole.

17. A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

18. A method for treating a disorder manifesting hypersecretion of CRF in a mammal comprising administering to the mammal a pharmaceutically effective amount of the pharmaceutical composition of claim 17.

19. A method according to claim 18, wherein the disorder is an affective disorder, an anxiety-related disorder, a feeding disorder, a stress-induced immunosuppressive disorder, an inflammatory disorder or a substance abuse or withdrawal disorder.

20. A method according to claim 18, wherein the disorder is irritable bowel syndrome.

21. A method according to claim 18, wherein the disorder is depression.

22. A method according to claim 18, wherein the disorder is anxiety.

23. A method according to claim 18, wherein the disorder is obsessive-compulsive disorder.

24. A method according to claim 18, wherein the disorder is stroke.